TOP TEN perturbations for 1115_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1115_at
Selected probe(set): 206390_x_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1115_at (206390_x_at) across 6537 perturbations tested by GENEVESTIGATOR:

stem cell differentiation study 50 (IRF6 shRNA; ASC; proerythroblast) / stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)

Relative Expression (log2-ratio):-6.732767
Number of Samples:3 / 4
Experimental stem cell differentiation study 50 (IRF6 shRNA; ASC; proerythroblast)
Proerythroblast differentiated from IRF6 (interferon regulatory factor 6) shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing shRNA targeting IRF6 gene with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation.
Control stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)
Proerythroblast differentiated from control shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing control shRNA with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation.

stem cell differentiation study 50 (IRF2 shRNA; ASC; proerythroblast) / stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)

Relative Expression (log2-ratio):-6.5737686
Number of Samples:3 / 4
Experimental stem cell differentiation study 50 (IRF2 shRNA; ASC; proerythroblast)
Proerythroblast differentiated from IRF2 (interferon regulatory factor 2) shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing shRNA targeting IRF2 gene with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation.
Control stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)
Proerythroblast differentiated from control shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing control shRNA with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation.

B-ALL study 1 (hyperdiploid) / normal bone marrow sample

Relative Expression (log2-ratio):-5.2134895
Number of Samples:40 / 74
Experimental B-ALL study 1 (hyperdiploid)
Bone marrow samples of patients with hyperdiploid B-ALL (hyperdiploid karyotype).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

precursor-B-ALL study 1 (t(1;19)(q23,q13)) / normal bone marrow sample

Relative Expression (log2-ratio):-4.9403353
Number of Samples:36 / 74
Experimental precursor-B-ALL study 1 (t(1;19)(q23,q13))
Bone marrow samples of patients with precursor B-ALL (t(1;19)(q23,q13)/E2A-PBX1).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

AML study 1 (inv(16)/t(16;16)) / normal bone marrow sample

Relative Expression (log2-ratio):-4.9372044
Number of Samples:28 / 74
Experimental AML study 1 (inv(16)/t(16;16))
Bone marrow samples of patients with acute myeloid leukemia (AML) with genetic aberration (inv(16)/t(16;16)).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

kidney transplantation study 12 (4 week) / normal T-cell (CD4+) sample

Relative Expression (log2-ratio):4.8955717
Number of Samples:2 / 5
Experimental kidney transplantation study 12 (4 week)
CD4+ T-cell samples derived from kidney transplant patients 4 weeks post-transplantation. Samples were collected 4 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH).
Control normal T-cell (CD4+) sample
CD4+ T-cell samples derived from healthy control subjects.

precursor-B-ALL study 1 (t(11q23)) / normal bone marrow sample

Relative Expression (log2-ratio):-4.893299
Number of Samples:70 / 74
Experimental precursor-B-ALL study 1 (t(11q23))
Bone marrow samples of patients with precursor B-ALL (t(11q23)/MLL).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

T-ALL study 1 / normal bone marrow sample

Relative Expression (log2-ratio):-4.685384
Number of Samples:174 / 74
Experimental T-ALL study 1
Bone marrow samples of patients with T-ALL.
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

AML study 1 (t(8;21)(q22;q22)) / normal bone marrow sample

Relative Expression (log2-ratio):-4.6508474
Number of Samples:40 / 74
Experimental AML study 1 (t(8;21)(q22;q22))
Bone marrow samples of patients with acute myeloid leukemia (AML) with genetic aberration (t(8;21)(q22;q22)).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

c-ALL/pre-B-ALL study 1 / normal bone marrow sample

Relative Expression (log2-ratio):-4.516838
Number of Samples:233 / 74
Experimental c-ALL/pre-B-ALL study 1
Bone marrow samples of patients with c-ALL/pre-B-ALL (without t(9;22)(q34,q11)/BCR-ABL).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.